Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX-010 in HIV
NCT03407105Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2003
- Primary completion
- Feb 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab in human immunodeficiency virus infection (HIV), sponsored by Bristol Myers Squibb. Primary endpoints: Number of treatment induced dose limiting toxicities at 141 days, Grade of treatment induced DLTs at 141 days and 1 more. Started Apr 2003; status: completed.
02
Drugs
ipilimumab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03407105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03407105.